Maxim Group Downgrades Cyclo Therapeutics (CYTH) to Hold
Tweet
Share
E-mailGet Alerts CYTH Hot Sheet
Price: $1.28 -0.78%
Rating Summary:
0 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 3 | New: 43
Rating Summary:
0 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 3 | New: 43
Join SI Premium – FREE
Maxim Group analyst Jason McCarthy downgraded Cyclo Therapeutics (NASDAQ: CYTH) from Buy to Hold.
For an analyst ratings summary and ratings history on Cyclo Therapeutics click here. For more ratings news on Cyclo Therapeutics click here.
Shares of Cyclo Therapeutics closed at $1.11 yesterday.
You May Also Be Interested In
- Roth/MKM Downgrades Rain Oncology (RAIN) to Neutral 'Pending Outcome of Evaluation of Pipeline Expansion'
- Barclays Downgrades Millicom International Cellular SA (MIC:SS) (TIGO) to Equalweight
- BofA downgrades Hibbett (HIBB) by two notches to Sell citing 'significant slowdown'
Create E-mail Alert Related Categories
DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
